HIGHBuilt-in & outside partyProduct / Revenue mix
Duchenne products
“10-K Item 1: 'we have developed and commercialized the following four approved products for the treatment of Duchenne'”
SRPT · Concentration risk · 10-K extracted
Sarepta Therapeutics (SRPT) concentration risks
Updated
The most significant concentration Sarepta Therapeutics discloses is Duchenne products, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Sarepta Therapeutics’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH2
MEDIUM1
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
Catalent
“10-K Item 1: 'Catalent supports our clinical and commercial manufacturing demand for ELEVIDYS and our SRP-9003 LGMD program'”
MEDIUMOutside partySupplier
Aldevron
“10-K Item 1: 'Aldevron provides plasmids for ELEVIDYS and SRP-9003 and is expected to provide plasmid source material for any future gene therapy programs'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentration profile combines a high-share product focus with two manufacturing dependencies, creating a layered risk picture characteristic of a specialized rare-disease biotechnology company. The product side centers on four approved treatments for Duchenne, a high-share, mixed-character exposure: the concentration is structural in that the company has deliberately built its franchise around Duchenne as a therapeutic area, but the mixed character reflects both that strategic foundation and the idiosyncratic risk that regulatory or clinical developments affecting any one product could disproportionately affect the portfolio. On the supply side, Catalent supports clinical and commercial manufacturing for ELEVIDYS and the SRP-9003 program, a high-share dependency exposure. Reliance on a single contract manufacturer for commercial-stage and pipeline products at this scale means that operational disruptions, quality observations, or capacity constraints at Catalent could affect both product availability and program timelines across multiple assets simultaneously. A second supplier dependency involves Aldevron, which provides plasmid source material for ELEVIDYS and SRP-9003 and is expected to supply plasmid material for future gene therapy programs, a moderate-share dependency. Plasmids are an upstream input specific to gene therapy manufacturing where alternative sources can be difficult to qualify, making this a meaningful supply chain constraint despite its smaller disclosed share. Taken together, the concentration profile reflects the structural features of a gene therapy franchise: a narrow therapeutic focus supported by a limited manufacturing supply chain with limited near-term redundancy.
For the engine’s reasoning on SRPT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| SRPT● | Sarepta Therapeutics, Inc. | 2 | 1 | 0 | 3 |
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.